Methods of treating diseases with activated protein C

Details Methods of treating diseases with activated protein C Methods of treating diseases with activated protein C

2007-02-26

2009-12-29

O'Hara, Eileen B (Department: 1644)

Drug, bio-affecting and body treating compositions

Enzyme or coenzyme containing

Hydrolases

C514S002600

Reexamination Certificate

active

07638123

ABSTRACT:
Method of treating a disease or pathological condition with activated protein C or a compound having activated protein C activity by direct regulation of the expression of specific genes associated with the disease or pathological condition.

REFERENCES:
patent: 4775624 (1988-10-01), Bang et al.
patent: 4849403 (1989-07-01), Stocker et al.
patent: 4877608 (1989-10-01), Lee et al.
patent: 4981952 (1991-01-01), Yan
patent: 4992373 (1991-02-01), Bang et al.
patent: 5009889 (1991-04-01), Taylor et al.
patent: 5084273 (1992-01-01), Hirahara
patent: 5093117 (1992-03-01), Lawrence et al.
patent: 5112949 (1992-05-01), Vukovich
patent: 5175087 (1992-12-01), Ranby et al.
patent: 5196322 (1993-03-01), Bang et al.
patent: 5254532 (1993-10-01), Schwarz et al.
patent: 5395923 (1995-03-01), Bui-Khac et al.
patent: 5413732 (1995-05-01), Buhl et al.
patent: 5442064 (1995-08-01), Pieper et al.
patent: 5453373 (1995-09-01), Gerlitz et al.
patent: 5478558 (1995-12-01), Eibl et al.
patent: 5516650 (1996-05-01), Foster et al.
patent: 5831025 (1998-11-01), Ogata et al.
patent: 5962299 (1999-10-01), Miyata et al.
patent: 6008199 (1999-12-01), Grinnell et al.
patent: 6037322 (2000-03-01), Grinnell et al.
patent: 6156734 (2000-12-01), Grinnell
patent: 6159468 (2000-12-01), Carlson et al.
patent: 6162629 (2000-12-01), Baker et al.
patent: 6268337 (2001-07-01), Grinnell
patent: 6268344 (2001-07-01), Grinnell
patent: 6395270 (2002-05-01), Carlson et al.
patent: 6426071 (2002-07-01), Grinnell et al.
patent: 6436397 (2002-08-01), Baker et al.
patent: 6489296 (2002-12-01), Grinnell
patent: 6630137 (2003-10-01), Carlson et al.
patent: 7204981 (2007-04-01), Ciaccia et al.
patent: 3823519 (1990-01-01), None
patent: 0 314 095 (1989-05-01), None
patent: 0 326 014 (1989-08-01), None
patent: 0 357 296 (1989-08-01), None
patent: 0 315 968 (1993-03-01), None
patent: 0 662 513 (1995-07-01), None
patent: 0 726 076 (1996-08-01), None
patent: 0 445 939 (1997-05-01), None
patent: 0 318 201 (1998-11-01), None
patent: 01 226900 (1989-09-01), None
patent: 06 183996 (1994-07-01), None
patent: 07 097335 (1995-04-01), None
patent: 07 165605 (1995-06-01), None
patent: 08 301786 (1996-11-01), None
patent: 08 325161 (1996-12-01), None
patent: WO 91/12320 (1991-08-01), None
patent: WO 95/11966 (1995-05-01), None
patent: WO 97/20043 (1997-06-01), None
patent: WO 98/48818 (1998-11-01), None
patent: WO 99/20293 (1999-04-01), None
U.S. Appl. No. 10/635,865, filed Aug. 6, 2003, Carlson et al.
“Anti-inflammatory Therapies to Treat Sepsis and Septic Shock: A Reassessment,”Crit. Care Med. 25:1095-1100, 1997.
Barbour, et al., “Controversies in Thromboembolic Disease During Pregnancy: A Critical Review,”Obstet. Gynecol. 86 (4):621-633, 1995.
Bazarbachi, et al., “Changes in Protein C Factor VII and Endothelial Markers After Autologous Bone Marrow Transplantation: Possible Implications in the Pathogensis of Veno-Occlusive Disease,”Nouv Rev Fr Hematol 35:135-140, 1993.
Blamey, et al., “Protein C Antigen Levels in Major Abdominal Surgery: Relationships to Deep Vein Thrombosis, Malignancy and Treatment with Stanozolol,”Thromb. Haemost. 54:6223-625, 1985.
Butler, et al., “Yersinia pestisInfection in Vietnam. I. Clinical and Hematologic Aspects,”The Journal of Infectious Disease 129:S78-S84, 1976.
Carpenter, et al., “Purpura Fulminans in Pneumococcal Sepsis: Case Report and Review,”Scand J Infec Dis29:479-483, 1997.
Chabbat, et al., “The Behavior of Human Activated Protein C in the Plasma of Different Laboratory Animals,”Thromb. Haemost. 65:A1814, 1991.
Collins, et al., “Factor VIIa and Other Haemostatic Variables Following Bone Marrow Transplantation,”Throm. And Haemo. 72:28-32, 1994.
Collins, et al., “Pitfalls in Peripheral Vascular Surgery: Disseminated Intravascular Coagulation,”Am. J. Surgery 124:375-380, 1997.
Conard, et al., “Thrombosis and Pregnancy in Congenital Deficiencies in AT III, Protein C or Protein S: Study of 78 Women,”Throm. Haemost. 63:319-320, 1990.
Curreri, et al., “Coagulation Dynamics Following Thermal Injury,”Ann. Surg. 181:161-163, 1974.
Dahlback, et al., “Inherited Thrombophilia: Resistance to Activated Protein C as a Pathogenic Factor of Venous Thromboembolism,”Blood 85:607-614, 1995.
De Stefano, et al., “Thrombotic Risk During Pregnancy and Puerperium in Women with APC-Resistance—Effective Subcutaneous Heparin Prophylaxis in a Pregnancy Patient,”ThrombHaemost 74:793-794, 1995.
Esmon, “The Protein C Anticoaglant Pathway,”Arteriosclerosis&Thromb. 12:135-145, 1992.
Esmon, C.T., “Inflammation: The protein C pathway.”Fibrinolysis&Proteolysis, 11(Supp 1):143-148 (1997).
Esmon, C.T., “The Regulation of Natural Anticoagulant Pathways”Science, 235:1348-1352 (Mar. 1987).
Faioni, et al., “Naturally Occurring Anticoagulants and Bone Marrow Transplantation: Plasma Protein C Predicts the Development of Venocclusive Disease of the Liver,”Blood 81:3458-3462, 1993.
Fourier, et al., “Septic Shock, Multiple Organ Failure, and Disseminated Intravascular Coagulation,”Chest 101: 816-823, 1992.
Franz, et al., “Clinical Recognition and Management of Patients Exposed to Biological Warfare Agents,”Journal of the American Medical Assoc. 278(5):399-411, 1997.
Gerson, et al., “Severe Acquired Protein C Deficiency in Purpura Fulminans Associated with Disseminated Intravascular Coagulation: Treatment with Protein C Concentrate,”Pediatrics 91(2):418-422, 1993.
Gibaldi, “Anatomy of an Antibody, and Related Misadventures in Developing an Effective Treatment for Septic Shock,”Pharmacotherapy 13(4):302-308, 1993.
Gordon, et al., “Thrombotic Complications of BMT: Association with Protein C Deficiency,”Bone Marrow Transplan. 11:61-64, 1993.
Graybill, et al., “Complement and Coagulation in Rocky Mountain Spotted Fever,”Southern Medical Journal 66(4):410-413, 1973.
Grey, S.T., et al., “Selective Inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbolester,”Journal of Immunology, 153(8):3664-3672 (Oct. 15, 1994).
Grinnell, et al., “Trans-Activated Expression of Fully Gamma-Carboxylated Recombinant Human Protein C, An Antithrombotic Factor,”Bio/Technology 5: 1189-1192, 1987.
Gruber, A., et al., “Direct Detection of Activated Protein C in Blood from Human Subjects,”Blood, 79:2340-2328, 1992.
Haire, et al., “Multiple Organ Dysfunction Syndrome in Bone Marrow Transplantation,”JAMA 274:1289-1295, 1995.
Harper, et al., “Changes in the Natural Anticoagulants Following Bone Marrow Transplantation,”Bone Marrow Trans. 5:39-42, 1990.
Harper, et al., “Protein C Deficiency and Portal Thrombosis in Liver Transplantation in Children,”Lancet924-927, 1988.
Hill, et al., “Leptospiral Pneumonia,”Seminars in Respiratory Infections 12(1):44-49, 1997.
Howey, et al., “Preparation for Trials of Recombinant Activated Protein C in Sepsis; A pharmacokinetics and Dynamic Study in Healthy Men and Women,”Chest 112(3):89S, 1997.
LeClerc, J.R., “Low-Molecular Weight Heparin Prophylaxix in Surgical Patients,”Clin. Appl. Thrombosis/Hemostasis 3(3):153-156, 1997.
Koul, et al., “Haemostatic Abnormalities in Multidrug-Resistant Enteric Fever,”Acat Haematol 93:13-19, 1995.
Koutroubakis, I.E., et al., “Resistence to activated protein C and low levels of free protein S in Greek patients with inflammatory bowel disease,”American Journ. of Gastroenterology, 95(1):190-194 (2000).
LeClerc, J. R., “Low-Molecular Weight Heparin Prophylaxix in Surgical Patients,”Clin. Appl. Thrombosis/Hemostasis 3(3):153-156, 1997.
Lercari, et al., “Apheresis for Severe Malaria Complicated by Cerebral Malaria, Acute Respiratory Distress

Affiliated with

Also associated with

Rating

Methods of treating diseases with activated protein C does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of treating diseases with activated protein C, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating diseases with activated protein C will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4077544